Cargando…

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer

IMPORTANCE: Although the activity of pembrolizumab and lenvatinib (the only US Food and Drug Administration–approved immunotherapy for mismatch repair proficient endometrial cancer [MMRP EC]) is compelling, there are no biomarkers of response and most patients do not tolerate, do not respond to, or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konstantinopoulos, Panagiotis A., Gockley, Allison A., Xiong, Niya, Krasner, Carolyn, Horowitz, Neil, Campos, Susana, Wright, Alexi A., Liu, Joyce F., Shea, Meghan, Yeku, Oladapo, Castro, Cesar, Polak, Madeline, Lee, Elizabeth K., Sawyer, Hannah, Bowes, Brittany, Moroney, John, Cheng, Su-Chun, Tayob, Nabihah, Bouberhan, Sara, Spriggs, David, Penson, Richard T., Fleming, Gini F., Nucci, Marisa R., Matulonis, Ursula A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335244/ https://www.ncbi.nlm.nih.gov/pubmed/35900726 http://dx.doi.org/10.1001/jamaoncol.2022.2181

Ejemplares similares

Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial
por: Yap, Timothy A., et al.
Publicado: (2022)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
por: Rodon Ahnert, J., et al.
Publicado: (2023)

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer
por: Penson, Richard T, et al.
Publicado: (2023)

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
por: Yeku, Oladapo, et al.
Publicado: (2020)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
por: Batalini, Felipe, et al.
Publicado: (2022)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
por: Coquan, Elodie, et al.
Publicado: (2022)

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial
por: Schram, Alison M., et al.
Publicado: (2022)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2021)

The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors
por: Durairaj, Chandrasekar, et al.
Publicado: (2021)

PD-1 Inhibitor Therapy in a Patient with Preexisting P-ANCA Vasculitis: A Case Report and Review of the Literature
por: Ramos, Amanda, et al.
Publicado: (2020)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Evaluation of the potential for QTc prolongation with avelumab
por: Vugmeyster, Yulia, et al.
Publicado: (2019)

Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment
por: Guo, Cen, et al.
Publicado: (2022)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib
por: Li, Jiaguo, et al.
Publicado: (2020)

A Phase I trial of talazoparib in patients with advanced hematologic malignancies
por: Gopal, Ajay K, et al.
Publicado: (2021)

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
por: Klein, Florian G., et al.
Publicado: (2021)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies
por: Stasenko, Marina, et al.
Publicado: (2021)

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure
por: Lee, Elizabeth K., et al.
Publicado: (2019)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022)

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
por: Hoffman, Justin, et al.
Publicado: (2019)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy
por: Li, Si, et al.
Publicado: (2021)

Evaluation of the effect of P‐glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours
por: Elmeliegy, Mohamed, et al.
Publicado: (2020)

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
por: Del Pozo, Vanessa, et al.
Publicado: (2021)

Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
por: Schwarz, Florian, et al.
Publicado: (2022)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
por: Lee, Elizabeth K., et al.
Publicado: (2019)

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
por: Yeku, Oladapo O., et al.
Publicado: (2021)

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer
por: Blum, Joanne L., et al.
Publicado: (2022)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_33kjkk676fbkc1ibo5c1jb30g4